Beatriz Elizabeth Nielsen

Beatriz Elizabeth Nielsen

Auto-generated profile, based on publicly available information

Beatriz Elizabeth Nielsen

University of Colorado Anschutz Medical Campus University of Colorado Anschutz Medical Campus

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2017 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
CBCecilia Bouzat
Cecilia Bouzat
MLMatías Lasala
Matías Lasala
BNBeatriz Elizabeth Nielsen
Beatriz Elizabeth Nielsen
JCJeremías Corradi
Jeremías Corradi
MEMaría del Carmen Esandi
María del Carmen Esandi
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand‐gated ion channels involved in many physiological and pathological processes. In vertebrates, there are seventeen different nAChR subunits that combine to yield a variety of receptors with different pharmacology, function, and localization. The homomeric α7 receptor is one of the most abundant nAChRs in the nervous system and it is also present in non‐neuronal cells. It plays important roles in cognition, memory, pain, neuroprotection, and inflammation. Its diverse physiological actions and associated disorders have made of α7 an attractive novel target for drug modulation. Potentiation of the α7 receptor has emerged as a novel therapeutic strategy for several neurological diseases, such as Alzheimer's and Parkinson's diseases, and inflammatory disorders. In contrast, increased α7 activity has been associated with cancer cell proliferation. The presence of different drug target sites offers a great potential for α7 modulation in different pathological contexts. In particular, compounds that target allosteric sites offer significant advantages over orthosteric agonists due to higher selectivity and a broader spectrum of degrees and mechanisms of modulation. Heterologous expression of α7, together with chaperone proteins, combined with patch clamp recordings have provided important advances in our knowledge of the molecular basis of α7 responses and their potential modulation for pathological processes. This review gives a synthetic view of α7 and its molecular function, focusing on how its unique activation and desensitization features can be modified by pharmacological agents. This fundamental information offers insights into therapeutic strategies. image

1 August 2016 in Neuropharmacology
Verified
Journal Article
Closed access
NANatalia D. Andersen
Natalia D. Andersen
BNBeatriz E. Nielsen
Beatriz E. Nielsen
JCJeremías Corradi
Jeremías Corradi
MTMaría F. Tolosa
María F. Tolosa
DFDominik Feuerbach
Dominik Feuerbach
CBCecilia Bouzat
Cecilia Bouzat

22 November 2024 in Science Advances
Verified
Journal Article
Open access
BNBeatriz E. Nielsen
Beatriz E. Nielsen
CFChristopher P. Ford
Christopher P. Ford
A dynamic equilibrium between dopamine and acetylcholine (ACh) is essential for striatal circuitry and motor function, as imbalances are associated with Parkinson’s disease (PD) and levodopa-induced dyskinesia (LID). Conventional theories posit that cholinergic signaling is pathologically elevated in PD as a result of increased ACh release, which contributes to motor deficits. However, using approaches to measure receptor-mediated signaling, we found that, rather than the predicted enhancement, the strength of cholinergic transmission at muscarinic M4 receptor synapses on direct pathway medium spiny neurons was decreased in dopamine-depleted mice. This adaptation was due to a reduced postsynaptic M4 receptor function, resulting from down-regulated receptors and downstream signaling. Restoring M4 transmission unexpectedly led to a partial alleviation of motor deficits and LID dyskinetic behavior, revealing an unexpected prokinetic effect in addition to the canonical antikinetic role of M4 receptors. These findings indicate that decreased M4 function differentially contributes to parkinsonian and LID pathophysiology, representing a promising target for therapeutic intervention.

8 January 2018 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
BNBeatriz E. Nielsen
Beatriz E. Nielsen
TMTeresa Minguez
Teresa Minguez
IBIsabel Bermudez
Isabel Bermudez
CBCecilia Bouzat
Cecilia Bouzat
The α7 nicotinic receptor is a promising drug target for neurological and inflammatory disorders. Although it is the homomeric member of the family, a novel α7β2 heteromeric receptor has been discovered. To decipher the functional contribution of the β2 subunit, we generated heteromeric receptors with fixed stoichiometry by two different approaches comprising concatenated and unlinked subunits. Receptors containing up to three β2 subunits are functional. As the number of β2 subunits increases in the pentameric arrangement, the durations of channel openings and activation episodes increase progressively probably due to decreased desensitization. The prolonged activation episodes conform the kinetic signature of α7β2 and may have an impact on neuronal excitability. For activation of α7β2 receptors, an α7/α7 binding-site interface is required, thus indicating that the three β2 subunits are located consecutively in the pentameric arrangement. α7-positive allosteric modulators (PAMs) are emerging as novel therapeutic drugs. The presence of β2 in the pentamer affects neither type II PAM potentiation nor activation by an allosteric agonist whereas it impairs type I PAM potentiation. This first single-channel study provides fundamental basis required to decipher the role and function of the novel α7β2 receptor and opens doors to develop selective therapeutic drugs.

1 December 2019 in Neuropharmacology
Verified
Journal Article
Closed access
BNBeatriz Elizabeth Nielsen
Beatriz Elizabeth Nielsen
IBIsabel Bermudez
Isabel Bermudez
CBCecilia Bouzat
Cecilia Bouzat